General Information of Drug (ID: DM8RIA6)

Drug Name
RGH-1756 Drug Info
Synonyms
NCGC00015909-01; Lopac-S-106; AC1L1JZN; Prestwick3_000443; Lopac0_001152; BSPBio_000486; BPBio1_000536; CHEBI:93632; CTK7A2978; BDBM50000687; ZINC100071375; CCG-205226; NCGC00015909-03; NCGC00162355-01; NCGC00016970-01; NCGC00015909-02; NCGC00015909-04; AB00513839; CAS-105538-73-6; BRD-K93280214-004-02-3; 6-amino-1-(3-carboxypropyl)-3-(4-methoxyphenyl)pyridazin-1-ium; 4-[6-amino-3-(4-methoxyphenyl)pyridazin-1-ium-1-yl]butanoic acid; 6-Amino-1-(3-carboxy-propyl)-3-(4-methoxy-phenyl)-pyridazin-1-ium
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Terminated [1]
Cross-matching ID
PubChem CID
9868983
CAS Number
CAS 207277-37-0
TTD Drug ID
DM8RIA6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D3 receptor (D3R) DTT DRD3 1.379 2.446 1.233 1.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Schizophrenia
ICD Disease Classification 6A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D3 receptor (D3R) DTT DRD3 2.84E-03 0.13 2
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.